Transforming Risk Management and Stakeholder Engagement in Clinical Trials: A PM's Journey

ABC Pharmaceuticals, a pioneering biotech firm known for its cutting-edge research in therapeutic innovations. Amidst their quest for groundbreaking treatments, they encountered a pivotal juncture during a Phase IIb/III cardiovascular trial. Regulatory shifts, supply chain vulnerabilities, and safety concerns cast a shadow over their aspirations. This is the story of how the Clinical Project Manager, redefined risk management, embracing challenges as catalysts for innovation while transforming stakeholder conversations.

ABC Pharmaceuticals, driven by innovation, harbored a risk-averse culture—prioritizing safety and efficacy

without aggressively embracing uncertainties. CPM recognized the need for a paradigm shift. He envisioned risk not merely as a hurdle but as a potential driver of transformative change within the trial landscape.

The Evolution of Risk Management:

Identifying the Challenges: ABC Pharmaceuticals’ initial risk assessments identified potential disruptions:
Evolving Regulations: Heightened regulatory changes posed threats to trial protocols and timelines.
Supply Chain Fragility: Vulnerabilities in the supply chain threatened trial consistency and drug availability.
Safety Concerns: Unforeseen adverse events could jeopardize patient safety and trial integrity.
The Traditional Approach: The organization’s conventional risk mitigation strategies leaned towards caution, focusing on compliance and safety nets, lacking the agility to navigate swiftly evolving landscapes.
A Paradigm Shift: CPM spearheaded a new approach—a proactive, aggressive stance towards risk. He engaged stakeholders in rigorous risk workshops, fostering a culture of risk awareness and strategic thinking. Through spirited discussions, risks transformed from ominous shadows into stepping stones for innovation:

Embracing Risk as Opportunity:

Regulatory Changes: Rather than fearing regulatory shifts, CPM advocated for adaptive trial designs. He engaged regulatory bodies in proactive dialogues, positioning ABC as a frontrunner in compliance and innovation.
Supply Chain Vulnerabilities: Collaborative workshops with vendors cultivated risk-sharing partnerships. Zephyr diversified suppliers and implemented agile contingency plans, fortifying the supply chain against disruptions.
Safety Concerns: CPM championed a safety-first approach by establishing a robust safety monitoring committee. Real-time safety reviews and agile protocol amendments ensured patient safety while leveraging safety insights for innovative trial designs.

Communication and Collaboration: CPM's Approach to Stakeholder Communication:

Transparency and Clarity: Candid discussions elucidated risks with clarity while emphasizing potential opportunities within each challenge.
Tailored Messaging: Crafted messages resonated with each stakeholder’s objectives and concerns.
Fostering Collaboration: Cultivated open dialogue, encouraging feedback and collaborative problem-solving.

Engaging Stakeholders:

The Sponsor: CPM engaged the sponsor in frequent updates, illustrating risks with comprehensive yet digestible presentations. He highlighted potential opportunities within risks, aligning strategies with the sponsor’s goals—earning trust and fostering a collaborative partnership.
Senior Management: CPM’s presentations to senior management were not just about risks but about visionary opportunities. He tailored messages showcasing agility and innovation within risks, garnering support for adaptive decision-making and fostering a culture of resilience.
Vendor Relationships: Transparent conversations with vendors, sharing risk-sharing strategies, and fostering a symbiotic relationship positioned vendors as strategic allies invested in the trial’s success.
Enhancing Communication: Utilized visual aids like risk matrices and impact graphs, making complex risks more accessible and actionable for stakeholders. Crafted scenarios illustrating potential risk consequences and corresponding opportunities, aiding stakeholders in grasping the holistic impact of risks.

Outcomes and Reflections: CPM’s adept communication transformed stakeholder engagement: The sponsor became a collaborative partner in risk mitigation and opportunity realization. Senior management embraced a culture of innovation and agile decision-making. Vendor relationships evolved into collaborative risk-sharing partnerships. CPM's finesse in communication reshaped ABC Pharmaceuticals' approach to risk management. His narrative of opportunities within risks fostered a culture where uncertainties were embraced, not feared—catalyzing the journey towards trial success and innovation.

Comments

CORONIL exposing drug development process/approval in India?

CORONIL exposing drug development process/approval in India? CORONIL has launched in India from Patanjali and no formal authority is aware on this on 23 Jun 2020. Paid media showing live coverage of launching of CORNIL and friends and family members celebrated. Main stream media does not know anything about clinical trials or drug development process as we know their main focus would be on religions, Indo-Pak thats it. Hence main stream media did not ask any relevant questions to Baba ji who sits in laboratory with raw materials and as usual media did not involve any relevant panelist. On 23 Jun 2020 evening, AYUSH ministry finally informed (after launching and completing of this coverage )that this scientific study are not known to ministry and asked Patanjali to stop this advertisements of Ayurvedic drugs and are regulated under the provision of Drugs and Magic Remedies Act 1954 and rules thereafter and the directives issued by the central government in the wake of COVID

A Landmark Revolution: The I-SPY 2 Trial's Transformative Impact on Breast Cancer Treatment

Background: A Visionary Scientist's Mission: In the early 2000s, breast cancer was a relentless adversary, affecting millions of women worldwide. Dr. Laura Esserman, a distinguished oncologist, emerged as a beacon of hope in the battle against this formidable disease. Driven by her unwavering commitment to improving outcomes for breast cancer patients, she embarked on a mission to transform breast cancer care. Dr. Esserman's unique background as both a clinician and researcher provided her with invaluable insights. She saw the urgent need to revolutionize the traditional clinical trial model, which often moved at a snail's pace. Her vision and dedication paved the way for a groundbreaking study that would leave an indelible mark on the clinical trial industry. The I-SPY 2 Trial: An Innovation in Design : The I-SPY 2 Trial was no ordinary clinical trial; it was a groundbreaking endeavor characterized by its innovative and adaptive design. Here's why it became a game-cha

SPRINT in Clinical Trials Industry

Nobody knows everything: Nobody knows everything, not even the CEO. Need to incorporate information from many sources. Instead, the information is distributed asymmetrically across the team and across the company. In this process, we have got to gather it and make sense of it and asking the experts is the best and fastest way to do that. With luck, we chose our work because of bold vision. We want to deliver that vision to the world whether it is a message or service or an experience software or even a story or an idea. But bringing a vision to life is difficult. It I s always easy to get in endless emails, deadline that slip, meeting that burn up day, a long term projects based on questionable assumptions. It does not have to be that way. If there is any idea, big challenge and not quite enough time and if we could not prove that idea was viable in that time, then it switches to different projects/ideas. We need encouragement in Clinical Trial industry on experiment not only in th

Unraveling the Challenges of Unstructured Site Management Organizations (SMOs) in India's Clinical Trial Sector with a Unified Approach

Clinical research in India has witnessed substantial growth in recent years, with Site Management Organizations (SMOs) playing a pivotal role in conducting trials efficiently. However, challenges arise when dealing with unorganized SMOs, which lack regulatory oversight and financial transparency. This case study explores the issues stemming from such SMOs and offers a comprehensive strategy to mitigate risks and ensure successful clinical trials in India. Understanding the Unorganized SMO Landscape : Insights into the Growth of Unorganized SMOs in India and the Reasons Behind Their Frequent Closure: The landscape of Site Management Organizations (SMOs) in India has witnessed exponential growth in recent years, with multiple SMOs often operating within a single research site. This proliferation can be attributed to several factors, primarily the absence of robust regulatory oversight and accountability mechanisms specific to SMOs in the clinical research ecosystem. Lack of Regulator

The Impact of Genetic Differentiation Across Regions: The Case of Drug Responses and Clinical Trials

Genetic differentiation across regions can significantly impact how populations respond to drugs. Variations in genetic makeup mean that a medication might be effective for one group but less so, or even harmful, for another. This variability underscores the importance of tailored clinical trials and has implications for the recent CDSCO notification on waiving clinical trials. Here, we’ll explore examples where genetic differences have influenced drug efficacy and safety, highlighting the importance of considering these differences in drug approval processes. Warfarin and Genetic Variability Case Study: Warfarin is a widely used anticoagulant prescribed to prevent blood clots. The drug's dosing is highly individualized, and genetic variations play a crucial role in how patients metabolize it. Variants in the CYP2C19 gene and the VKORC1 gene influence Warfarin’s effectiveness and risk of bleeding. Genetic Differentiation:In populations of European descent, certain genetic variants

Virtual Clinical Trial: A complete Remote Concept

Virtual Industry revenues will reach to $7.2 billion globally by the end of 2017 as in Greenlight Insight’s latest report. Anticipating modest growth in the short term, expects the Virtual industry to grow into a major global marketplace by 2021, reaching $74.8 billion in global revenues. Virtual industry remarkably uses cases including Tourism, Education, Sales and Marketing, designing and sports coaching. How about on Clinical Trial Industry? Clinical Trial industry is facing crisis, nearly 80% of trials do not meet enrollment timelines, and these delays can amount to $8 million in lost revenues per day, according to one estimate by Cutting edge information. But now the industry is preparing to bet on new trend: Virtual Clinical Trials. Virtual Clinical Trials represent a relatively new method of collecting safety and efficacy data from clinical trial participants. Imaging few scenario on this. Patients do not travel to sites. Devices (it can be mobile, watch, glass) link to th

Identification of Risk - Clinical Trials

Potential Risks is an essential part because Clinical Trials projects tend to be time constrained, post huge technical challenges and suffer from adequate resources. Not all the risks are equally important, should focus on risks that can materially affect project objectives or uncertainty that matters. There are numbers of factors can be internal, such as available resources, skills level of human resources, funding availability, management approach, time constraints etc. Risks also vary depending on the stakeholder: subjects, study team, sponsor, competent authorities, target population and that is why stakeholders education, awareness, engagement and support are critical success factors for project risk management. Organizational and stakeholder risk attitudes and risk tolerances must be explicitly identified and managed before and during the project. Clinical Trials process may be divided into three main steps, each of these steps can be associated with number of more or l

From Darkness to Light: The Stanford Prison Experiment and the Ethical Evolution of Modern Clinical Trials

Once upon a time, in the early 1970s, a young psychologist named Philip Zimbardo embarked on a groundbreaking experiment at Standford university that would forever change the way we look at human behavior and research ethics. It began with an ad in the classifieds. Male college students needed for psychological study of prison life. $15 per day for 1–2 weeks. More than 70 people volunteered to take part in the study, to be conducted in a fake prison housed inside Jordan Hall, on Stanford’s Main Quad. The leader of the study was 38-year-old psychology professor Philip Zimbardo. He and his fellow researchers selected 24 applicants and randomly assigned each to be a prisoner or a guard. Zimbardo encouraged the guards to think of themselves as actual guards in a real prison. He made clear that prisoners could not be physically harmed, but said the guards should try to create an atmosphere in which the prisoners felt “powerless.” The study began on Sunday, August 17, 1971. But no one knew

Six Sigma in Clinical Trials

Process improvement techniques increasingly have been applied outside manufacturing for examples software development and healthcare . I Concerns the potential use of lean and six sigma to improve the process involved in clinical research. Improving quality, avoiding delays and errors and speeding up the time to implementation of biomedical discoveries is primary objective. Reducing the time between biomedical research discoveries and their adoption into clinical practice requires increased co-ordination, systematic planning. Better co-ordination, timeliness, efficiency and value of clinical research can be achieved by applying the set of principles, practices and method represented by Lean and Six sigma. Lean thinking involves a set of principles, practices and methods or designing, improving and managing process. Lean process reflects the goal of continually reducing waste and improving work flow to efficiently produce a product or service that is received to be or high val

Eyes On Trials

Search This Blog